Nanomaterial Delivery Systems for mRNA Vaccines

The recent success of mRNA vaccines in SARS-CoV-2 clinical trials is in part due to the development of lipid nanoparticle delivery systems that not only efficiently express the mRNA-encoded immunogen after intramuscular injection, but also play roles as adjuvants and in vaccine reactogenicity. We pr...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2021-01, Vol.9 (1), p.65
Main Authors: Buschmann, Michael D, Carrasco, Manuel J, Alishetty, Suman, Paige, Mikell, Alameh, Mohamad Gabriel, Weissman, Drew
Format: Article
Language:English
Subjects:
Adjuvants
Clinical trials
Coronaviruses
COVID-19
Deoxyribonucleic acid
DNA
Genes
ionizable lipid
Kinases
lipid nanoparticle
Lipids
mRNA
mRNA vaccines
Nanomaterials
Nanoparticles
Pharmaceutical industry
Protein expression
Proteins
Rabies
Review
RNA polymerase
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Tropical diseases
Tumor necrosis factor-TNF
vaccine
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The recent success of mRNA vaccines in SARS-CoV-2 clinical trials is in part due to the development of lipid nanoparticle delivery systems that not only efficiently express the mRNA-encoded immunogen after intramuscular injection, but also play roles as adjuvants and in vaccine reactogenicity. We present an overview of mRNA delivery systems and then focus on the lipid nanoparticles used in the current SARS-CoV-2 vaccine clinical trials. The review concludes with an analysis of the determinants of the performance of lipid nanoparticles in mRNA vaccines.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines9010065